Understanding tumor growth patterns helps guide treatment after lung cancer
When lung cancer treatment stops working, what happens next? New research reveals the answer may depend on how…
Durvalumab extends survival in SCLC but cost-effectiveness questioned
Durvalumab extends survival in small cell lung cancer while raising critical cost-effectiveness concerns. Researchers at the Sylvester Comprehensive…
Inflammation and immune suppression fuel aggressive SCLC behavior and spread
Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year…
Study links higher glycemic index diets with increased lung cancer risk
Background: In this study, researchers examined whether people who follow higher-GI or higher-GL diets have different risks of…
How COVID mRNA vaccines may make cancer treatments more effective
A new study reveals that SARS-CoV-2 mRNA vaccines can amplify immune checkpoint therapy in lung and skin cancers…
Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests
Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest…